Five Prime Therapeutics Inc (NASDAQ:FPRX)

18.49
Delayed Data
As of May 25
 +0.08 / +0.43%
Today’s Change
15.66
Today|||52-Week Range
48.87
-15.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$626.4M

Company Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Contact Information

Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
South San Francisco California 94080-7047
P:(415) 365-5600
Investor Relations:
(415) 365-5737

Employees

Shareholders

Mutual fund holders49.48%
Other institutional43.73%
Individual stakeholders16.89%

Top Executives

Aron M. KnickerbockerPresident, Chief Executive Officer & Director
Linda M. RubinsteinChief Financial & Accounting Officer
Helen CollinsChief Medical Officer & Senior Vice President
Bryan IrvingChief Scientific Officer & Executive VP
Kevin P. BakerSenior Vice President-Development Sciences